Business Context and Reporting Period
Company: Baxter International Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: Baxter operates three primary segments: BioScience (recombinant and plasma-based proteins), Medication Delivery (IV solutions, infusion pumps, anesthetics), and Renal (dialysis products). The company also provides transition services to Fenwal Inc. following the 2007 divestiture of its Transfusion Therapies business.
Key Financial Metrics
| Metric (in millions) | Q2 2008 | Q2 2007 | YTD 2008 | YTD 2007 |
|---|---|---|---|---|
| Net Sales | $3,189 | $2,829 | $6,066 | $5,504 |
| Net Income | $544 | $431 | $973 | $834 |
| Diluted EPS | $0.85 | $0.65 | $1.52 | $1.26 |
| Gross Margin | 51.0% | 49.2% | 49.6% | 48.3% |
| Operating Cash Flow (YTD) | $1,082 (2008) vs $946 (2007) | |||
| Cash and Equivalents | $2,147 (as of June 30, 2008) | |||
| Total Debt (Short + Long Term) | $3,234 (as of June 30, 2008) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% in Q2 and 10% year-to-date (YTD) compared to the prior year. Excluding the divested Transfusion Therapies business, sales growth was 13% in Q2 and 11% YTD. Foreign currency fluctuations provided an 8 percentage point benefit in Q2 and 7 percentage points YTD.
- Profitability: Net income rose 26% in Q2 and 17% YTD. Gross margin improved by 1.8 percentage points in Q2 and 1.3 points YTD, driven by product mix shifts (ADVATE, liquid IGIV) and manufacturing efficiencies, partially offset by raw material costs and special charges.
- Special Charges: YTD 2008 results included $53 million in charges related to COLLEAGUE infusion pump remediation delays and $19 million related to a heparin product recall. These charges reduced gross margin by 1.2 percentage points YTD.
- Segment Performance:
- BioScience: Sales up 16% (Q2) and 11% (YTD); Pre-tax income up 22%.
- Medication Delivery: Sales up 12% (Q2) and 10% (YTD); Pre-tax income up 21% (Q2) but down 8% (YTD) due to special charges.
- Renal: Sales up 8% (Q2) and 7% (YTD); Pre-tax income down 14% (Q2) and 15% (YTD) due to lost tenders and increased R&D/marketing spend.
Guidance, Outlook, Risks, and Unusual Items
- Guidance: Management anticipates an effective tax rate of approximately 19.0% for the full year 2008, excluding special items.
- Capital Allocation: The company repurchased $933 million of stock YTD 2008. As of June 30, 2008, $2.2 billion remained available under share repurchase authorizations. Dividends were increased to $0.2175 per share quarterly.
- Regulatory Risks (Unusual Items):
- COLLEAGUE Infusion Pumps: Shipments remain held in the U.S. pending FDA approval of remediation. A $53 million charge was recorded in Q1 2008 for delays and asset impairments. Remaining reserves are $86 million.
- Heparin Recall: A $19 million charge was recorded in Q1 2008 for the recall of heparin sodium injection products due to adverse reactions. Remaining cash reserves are expected to be utilized by end of 2008.
- Legal Proceedings: Significant litigation includes patent disputes (ADVATE, Sevoflurane), product liability claims (HIV/HCV from historical factor concentrates, autism/thimerosal), and pricing investigations (Medicare/Medicaid).
- Outlook: Management expects continued growth driven by ADVATE and liquid IGIV adoption, though risks remain regarding regulatory approvals, raw material costs, and foreign currency fluctuations.
Investor Verification Checklist
- Regulatory Resolution: Verify the timeline for FDA approval to resume sales of COLLEAGUE infusion pumps and the adequacy of the $86 million remaining reserve.
- Heparin Litigation: Monitor the status of the ~40 lawsuits filed regarding heparin adverse reactions and potential additional costs beyond the current reserve.
- Foreign Currency Impact: Assess the sustainability of sales growth given the significant 7-8 percentage point contribution from a weakening U.S. Dollar.
- Debt Structure: Review the impact of the new $500 million senior unsecured notes issued in May 2008 and the settlement of cross-currency swaps on future interest expense.
- Segment Margins: Analyze the Medication Delivery segment's ability to recover pre-tax income margins in the second half of 2008 following the Q1 special charges.